May 12, 2025
Nature Communications

Transcriptome analysis of archived tumors by Visium, GeoMx DSP, and Chromium reveals patient heterogeneity

Recent advancements in probe-based, full-transcriptome technologies for FFPE tissues, such as Visium CytAssist, Chromium Flex, and GeoMx DSP, enable analysis of archival samples, facilitating the generation of data from extensive cohorts. However, these methods can be labor-intensive and costly, requiring informed selection based on research objectives.

We compare these methods on FFPE tumor samples in Breast, NSCLC and DLBCL showing 1) good-quality, highly reproducible data from all methods; 2) GeoMx data containing cell mixtures despite marker-based preselection; 3) Visium and Chromium outperform GeoMx in discovering tumor heterogeneity and potential drug targets. We recommend the use of Visium and Chromium for high-throughput and discovery projects, while the manually more challenging GeoMx platform with targeted regions remains valuable for specialized questions.

Authors

Yixing Dong, Chiara Saglietti, Quentin Bayard, Almudena Espin Perez, Sabrina Carpentier, Daria Buszta, Stephanie Tissot, Rémy Dubois, Atanas Kamburov, Senbai Kang, Carla Haignere, Rita Sarkis, Sylvie Andre, Marina Alexandre Gaveta, Silvia Lopez Lastra, Nathalie Piazzon, Rita Santos, Katharina von Loga, Caroline Hoffmann, George Coukos, Solange Peters, Vassili Soumelis, Eric Yves Durand, Laurence de Leval, Raphael Gottardo, Krisztian Homicsko & Elo Madissoon